Cellipont Bioservices marks a significant achievement with its 100th GMP batch release, reflecting commitment to quality and client trust in cell therapy.

Cellipont Bioservices and Xiogenix publish a new white paper discussing innovative automated solutions for enhancing the scalability of cell therapy manufacturing processes.

Cellipont Bioservices' Texas operation has successfully driven six client programs towards IND submissions, showcasing its strength in cell therapy manufacturing and development.

THE WOODLANDS, Texas, Sept. 3, 2026 /PRNewswire/ -- Cellipont Bioservices, a cell therapy contract development and manufacturing organization, today announced that its Texas facility has supported six client projects to date that are expected to reach Investigational New Drug application...

Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility THE WOODLANDS, Texas, July 28, 2026 — Cellipont Bioservices, a cell...

The collaboration will focus on the production of delivery methods for complex cell therapies.

The collaboration will focus on scaling up the manufacturing of stem cells using Ronawk’s platform.

Enzene, Veranova report their respective site expansions; Ottimo partners with Lotte; UCB plans US factory; deals for Lifecore, Cellipont, TerraPower, Nusano, ITM in manufacturing roundup.

Reported Wednesday, Oct 29 - 8:34am EDT (TheFly subscription required to read more.)

Cellipont and BobcatBio are partnering to advance macrophage cell therapy for solid tumors, offering promising new treatment options for cancer patients.

Cellipont Bioservices and Soter Bio have joined forces to enhance U.S. cell therapy manufacturing through strategic collaboration and integrated solutions for biomanufacturing.

Cellipont Bioservices has enhanced its capabilities with a new ballroom-style cleanroom and 50-liter bioreactor, driving advancements in cell therapy production.

Cellipont Bioservices partners with Ronawk to enhance the scalability and quality of mesenchymal stem cells, addressing industry challenges in regenerative medicine.

Cellipont Bioservices enters a partnership with Ernexa Therapeutics to accelerate clinical trials for ERNA-101, targeting ovarian cancer treatment through cell therapy.

Cellipont Bioservices and CellVax Therapeutics are enhancing their collaboration to advance cGMP manufacturing of a groundbreaking personalized immunotherapy for GI cancers.

Bionique Testing Laboratories and Cellipont Bioservices have joined forces with a goal to accelerate the adoption of rapid mycoplasma testing in the growing field of cell and gene therapy manufacturing.

Cellipont Bioservices joins forces with Optieum Biotechnologies to enhance the cGMP manufacturing of a new CAR-T therapy targeting glioblastoma. This collaboration aims to revolutionize cancer treatment.

Cellipont Bioservices collaborates with Secretome Therapeutics for cGMP manufacturing of STM-01, a novel therapy targeting heart conditions.

Cellipont Bioservices partners with Xiogenix to enhance access to advanced filling systems, improving efficiency in biopharmaceutical manufacturing.

CanCan Jelly: 11 affiliate products from etsy matched!

Marker Therapeutics (NASDAQ: MRKR) reported Q3 2025 results and program updates on Nov 14, 2025. Key clinical highlights include a 66% objective response rate and 50% complete response rate for MT-601 in relapsed NHL from the Phase 1 APOLLO study (8/12 ORR; 6/12 CR), with five responses ≥6 months and three ≥12 months. No DLTs or ICANS observed. The company treated the first patient in its Off-the-Shelf RAPID study and signed a cGMP manufacturing collaboration with Cellipont. Marker raised approximately $10.0 million via ATM; cash and restricted cash totaled $19.0 million at 9/30/25, funding operations into Q3 2026 under current assumptions.

Ernexa Therapeutics (Nasdaq: ERNA) participated in a Virtual Investor “What This Means” segment on Nov. 6, 2025 to discuss a recently announced partnership with Cellipont Bioservices.The agreement covers Engineering, Differentiation, and Production (EDP) activities to advance ERNA-101, Ernexa’s lead cell therapy for ovarian cancer, into clinical manufacturing and clinical trials. President and CEO Sanjeev Luther represented the company in the segment. The presentation recording is available via the Virtual Investor platform.

Cellipont Bioservices and Ernexa Therapeutics (Nasdaq: ERNA) announced a collaboration on Oct 29, 2025 to advance ERNA-101, Ernexa's lead allogeneic iMSC cell therapy for ovarian cancer, into clinical manufacturing and trials. The agreement covers Engineering, Differentiation, and Production (EDP) activities and cGMP development and scale-up of the ERNA-101 manufacturing process.ERNA-101 is an off-the-shelf iMSC therapy designed to reprogram immunologically "cold" tumors to "hot" ones; preclinical data were presented at AACR and ASCO. The partnership targets translating preclinical promise into a clinically viable therapy.

THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is...